MAP2K7 and melanoma: It is believed that inhibiting both BRAF and MEK greatly can improve clinical outcomes for melanoma patients by slowing or preventing the development of resistance to BRAFi alone.337 In Table 3, we have compiled an update overview of clinical studies related to combination of BRAFi and MEKi based on information from the ClinicalTrials.go database.